The share price of CSL Ltd (ASX: CSL) has experienced a significant downturn in recent months, shedding nearly 50% of its value since August 2025. However, industry experts are suggesting that this prominent ASX healthcare stock may be poised for a substantial recovery, potentially reclaiming much of the lost ground. CSL, a global biotechnology powerhouse, is renowned for its diverse range of healthcare products, including vital blood plasma-derived treatments and essential vaccines.
A Beacon of Optimism from UBS
Recently, a note released by UBS has provided investors with a compelling reason for renewed optimism regarding CSL’s prospects. The brokerage firm has expressed a positive outlook on the biotech giant, highlighting key areas of growth and potential.
Strong Momentum for Andembry
A significant driver of this positive sentiment is the rapid adoption of CSL’s new therapy, Andembry, since its launch in mid-2025. UBS reports that over 1,000 patients are already benefiting from this treatment. This figure represents an estimated 15% of patients receiving prophylactic treatment across the major markets where Andembry has received approval.
With a US price point hovering around $400,000, UBS anticipates that this early traction will not only bolster CSL’s sales significantly in the latter half of the 2026 financial year but also sustain this strong performance well into FY27.
Hereditary Angioedema (HAE) Market Dynamics
UBS’s projections for CSL’s hereditary angioedema (HAE) market share may prove to be on the conservative side. The brokerage firm has factored in potential competitive pressures within its forecasts, leading to an expectation that CSL’s HAE market share will peak at 27% in FY27. This represents a notable increase from its estimated 20% share in FY25.
This cautious approach by UBS acknowledges several factors:
- Gradual Switching: The brokerage anticipates a slow but steady transition of patients from existing, incumbent therapies, including Haegarda.
- Emerging Competition: CSL will also face competition from other novel therapies, some of which are already approved, while others are progressing through clinical trials.
Despite these considerations, UBS believes there is “meaningful upside if Andembry takes more” market share. Their scenario analysis indicates a potential 9% boost to estimated FY30 earnings if CSL can capture 40% of the global HAE market. While this is an ambitious target, UBS deems it “credible given Andembry’s clear advantages in convenience and patient experience.” Furthermore, CSL’s extensive history and established presence within the HAE patient community position it favourably to challenge the current market leader, Takeda.
Is CSL a Buy?
Despite the prevailing market pessimism, UBS remains bullish on CSL’s future. The brokerage currently maintains a “buy” rating on the company, accompanied by a price target of $235. This price target suggests a potential upside of approximately 66% for the share price over the next twelve months. UBS forecasts that CSL could achieve a net profit of US$3.4 billion in FY26.
Strategic Considerations for Investors
While CSL presents a compelling investment case, it’s prudent for investors to conduct thorough due diligence. The market for biopharmaceutical products is dynamic, influenced by regulatory changes, scientific advancements, and competitive landscapes.
Key factors to consider when evaluating CSL include:
- Pipeline Development: The success of CSL’s research and development pipeline is crucial for its long-term growth. Continued innovation in areas like plasma-derived therapies and vaccines will be essential.
- Regulatory Approvals: Gaining and maintaining regulatory approvals for new products and indications in key global markets is paramount.
- Competitive Landscape: Monitoring the strategies and product developments of competitors, particularly in the HAE market, is vital.
- Economic and Geopolitical Factors: Broader economic conditions and geopolitical events can impact healthcare spending and supply chains, indirectly affecting CSL’s performance.
- Valuation Metrics: Investors should compare CSL’s valuation metrics against its peers and historical performance to assess its attractiveness.
The current market sentiment, while negative, may present an opportune moment for long-term investors to consider CSL, given the positive outlook from influential analysts like UBS and the company’s strong track record in delivering innovative healthcare solutions.
